Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)
Historic Change in Receivables for Avalo Therapeutics (AVTX) over the last 8 years, with Q4 2024 value amounting to -$387000.0.
- Avalo Therapeutics' Change in Receivables rose 7239.66% to -$387000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $475000.0, marking a year-over-year increase of 12664.05%. This contributed to the annual value of $475000.0 for FY2024, which is 12664.05% up from last year.
- As of Q4 2024, Avalo Therapeutics' Change in Receivables stood at -$387000.0, which was up 7239.66% from $965000.0 recorded in Q3 2024.
- In the past 5 years, Avalo Therapeutics' Change in Receivables ranged from a high of $2.3 million in Q3 2020 and a low of -$2.7 million during Q3 2021
- Over the past 5 years, Avalo Therapeutics' median Change in Receivables value was -$51500.0 (recorded in 2024), while the average stood at $25500.0.
- Per our database at Business Quant, Avalo Therapeutics' Change in Receivables crashed by 157766.08% in 2020 and then soared by 1905000.0% in 2023.
- Quarter analysis of 5 years shows Avalo Therapeutics' Change in Receivables stood at -$2.1 million in 2020, then soared by 209.44% to $2.3 million in 2021, then crashed by 73.38% to $605000.0 in 2022, then plummeted by 331.74% to -$1.4 million in 2023, then soared by 72.4% to -$387000.0 in 2024.
- Its last three reported values are -$387000.0 in Q4 2024, $965000.0 for Q3 2024, and -$2000.0 during Q2 2024.